SecSonar.com

Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Allogene Therapeutics, Inc. (ALLO) is a Biotechnology company based in US with a market capitalization of $524.6M. Free cash flow was negative at -$149.6M. This page tracks ALLO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 226 employees · IPO Oct 11, 2018

Valuation

Valuation & price

$2.00 · as of May 17, 2026 · -34.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.79

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$3.06$2.04$1.03Jul 25Dec 25Jul 26Jul 7, 25$1.16Jul 9, 25$1.21Jul 11, 25$1.28Jul 15, 25$1.24Jul 17, 25$1.24Jul 21, 25$1.32Jul 23, 25$1.66Jul 25, 25$1.50Jul 29, 25$1.40Jul 31, 25$1.23Aug 4, 25$1.10Aug 6, 25$1.06Aug 11, 25$1.03Aug 13, 25$1.04Aug 15, 25$1.10Aug 19, 25$1.05Aug 21, 25$1.12Aug 25, 25$1.16Aug 27, 25$1.16Aug 29, 25$1.13Sep 3, 25$1.12Sep 5, 25$1.15Sep 9, 25$1.14Sep 11, 25$1.17Sep 16, 25$1.18Sep 18, 25$1.21Sep 22, 25$1.17Sep 24, 25$1.23Sep 26, 25$1.25Sep 30, 25$1.24Oct 2, 25$1.29Oct 6, 25$1.38Oct 8, 25$1.47Oct 10, 25$1.23Oct 14, 25$1.23Oct 16, 25$1.27Oct 21, 25$1.26Oct 23, 25$1.21Oct 27, 25$1.23Oct 29, 25$1.22Oct 31, 25$1.24Nov 4, 25$1.11Nov 6, 25$1.05Nov 10, 25$1.18Nov 12, 25$1.23Nov 14, 25$1.23Nov 18, 25$1.31Nov 20, 25$1.24Nov 25, 25$1.36Nov 28, 25$1.46Dec 2, 25$1.34Dec 4, 25$1.44Dec 8, 25$1.45Dec 10, 25$1.48Dec 12, 25$1.51Dec 16, 25$1.54Dec 18, 25$1.42Dec 22, 25$1.47Dec 24, 25$1.40Dec 29, 25$1.38Jan 2, 26$1.35Jan 6, 26$1.41Jan 8, 26$1.49Jan 12, 26$1.67Jan 14, 26$1.70Jan 16, 26$1.63Jan 21, 26$1.60Jan 23, 26$1.72Jan 27, 26$1.53Jan 29, 26$1.59Feb 2, 26$1.87Feb 4, 26$1.80Feb 9, 26$1.69Feb 11, 26$1.65Feb 13, 26$1.80Feb 18, 26$2.27Feb 20, 26$2.05Feb 24, 26$2.29Feb 26, 26$2.73Mar 2, 26$2.65Mar 4, 26$2.53Mar 6, 26$2.30Mar 10, 26$2.71Mar 12, 26$2.47Mar 17, 26$2.27Mar 19, 26$2.22Mar 23, 26$2.44Mar 25, 26$2.33Mar 27, 26$2.26Mar 31, 26$2.44Apr 2, 26$2.48Apr 7, 26$2.62Apr 9, 26$2.91Apr 13, 26$3.06Apr 15, 26$2.17Apr 17, 26$2.39Apr 22, 26$2.39Apr 24, 26$2.31Apr 28, 26$2.19Apr 30, 26$2.13May 4, 26$2.26May 6, 26$2.31May 8, 26$2.28May 12, 26$2.30May 14, 26$2.14May 18, 26$1.94May 20, 26$1.90May 22, 26$2.00May 28, 26$2.25Jun 1, 26$2.15Jun 3, 26$2.00Jun 5, 26$1.88Jun 9, 26$1.82Jun 11, 26$1.88Jun 15, 26$1.94Jun 17, 26$1.96Jun 22, 26$2.10Jun 24, 26$2.05Jun 26, 26$2.13Jul 2, 26$2.08
$1.0352-week range$3.06
Loading valuation history…

Fundamentals

Key fundamentals

$524.6M

Market cap

—

Revenue growth (YoY)

100.0%

Gross margin

-$149.6M

Free cash flow (USD)

-$175.2M

Net debt

Net cash position

13.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$114.1MFY 2022$156.0KFY 2023$95.0KFY 2024$22.0KFY 2025$0.00
$0$0

Free cash flow by year

2017 → 2025

FY 2017$0.00FY 2018$-47.9MFY 2019$-188.1MFY 2020$-181.1MFY 2021$-206.3MFY 2022$-225.7MFY 2023$-239.2MFY 2024$-201.0MFY 2025$-149.6M
$0-$149.6M

Gross margin by year

2021 → 2024

FY 2021100.0%FY 2022-9063.5%FY 2023100.0%FY 2024100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 22, 2026Filing
  • 8-K eventCEO AppointmentMay 28, 2026Filing
  • 8-K eventEarnings ReleaseMay 13, 2026Filing
  • Quarterly report10-Q FiledMay 13, 2026Filing
  • Insider sellInsider Sell $22KYoshiyama Annie · SVP, Finance · $22.1KApr 23, 2026Filing
  • 8-K eventCommon Stock OfferingApr 15, 2026Filing
  • 8-K eventInterim Trial ResultsApr 13, 2026Filing
  • 8-K eventPublic Offering CommencedApr 13, 2026Filing
  • Insider sellInsider Sell $7KBeneski Benjamin Machinas · SVP, Chief Technical Officer · $7.2KApr 2, 2026Filing

Questions

Frequently asked questions

What is Allogene Therapeutics, Inc.'s market cap?

Allogene Therapeutics, Inc. (ALLO) has a market capitalization of $524.6M.

What is ALLO's P/E ratio?

A meaningful P/E ratio is not available for ALLO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ALLO's price-to-book (P/B) ratio?

ALLO trades at 1.79 times book value per share.

Are insiders buying ALLO stock?

SEC Form 4 filings show no open-market insider buys at Allogene Therapeutics, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

XOMA

XOMA Royalty Corp.

$523.3M

PRTA

Prothena Corporation plc

$528.8M

FDMT

4D Molecular Therapeutics, Inc.

$506.6M

ACRS

Aclaris Therapeutics, Inc.

$546.3M

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

$499.1M

MDXG

MiMedx Group, Inc.

$553.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.